PD173955
PD173955 is an orally active inhibitor of Src (IC50= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity[1][2][3][4].
Product Specifications
CAS Number
260415-63-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Bcr-Abl; Src
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PD173955.html
Purity
99.12
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=CC(SC)=C4)N=C3N1C
Molecular Formula
C21H16Cl2N4OS
Molecular Weight
443.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Moasser MM, et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59 (24) :6145-52. PMID: 10626805.|[2]Martinelli G, et al. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005 Nov;19 (11) :1872-9. |[3]Netzer WJ, et al. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A. 2017 Feb 7;114 (6) :1389-1394. |[4]Wolff NC, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105 (10) :3995-4003.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
EA101851 1x 48 Well (Pre-Coated)
Human IL-33 ELISA Kit, 1 x 48-well (pre-coated)
Sign In for Pricing
View Details 
HP230494 200 Reactions
DENND4A Human qPCR Primer Pair (NM_001144823)
Sign In for Pricing
View Details 
BNCB2098-500 1x 500 µL
Catenin, beta (CTNNB1) (CTNNB1/2098), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details